Abstract
Leptomeningeal Carcinomatosis (LC) refers to diffuse seeding of the leptomeninges by tumor metastases and is a rare presentation of solid tumors, particularly breast cancer, lung cancer and malignant melanoma in adults and hematogenous malignancies and primitive neuroectodermal tumor (PNET) in children. Recently, the incidence of LC has been reported to be increasing due to a longer overall survival obtained in patients treated with novel antineoplastic agents. The usual clinical presentation is a multifocal involvement of the neuraxis, with headache and radicular pain being the most common initial symptoms. The most frequent signs are motor deficits, altered mental status and cranial nerve involvement. The treatment of LC remains controversial and no straightforward guidelines exist in the literature. It has a bad prognosis and inevitably fatal outcome despite aggressive therapy.
Keywords: Leptomeningeal carcinomatosis, systemic therapy, intrathecal therapy, chemotherapy, radioterapy, methotrexate, capecitabine, temozolamide, ccnu, bcnu, thiotepa, ara-c, lung cancer, breast cancer, erlotinib, gefitinib, Ommaya, liposomal cytarabine, mafosfamide, topotecan, bevacizumab, medulloblastoma, DepoCyt, MRI, leukemia, CSF cytology
Central Nervous System Agents in Medicinal Chemistry
Title: Newer Avenues for the Treatment of Leptomeningeal Carcinomatosis
Volume: 11 Issue: 1
Author(s): Fausto Meriggi and Alberto Zaniboni
Affiliation:
Keywords: Leptomeningeal carcinomatosis, systemic therapy, intrathecal therapy, chemotherapy, radioterapy, methotrexate, capecitabine, temozolamide, ccnu, bcnu, thiotepa, ara-c, lung cancer, breast cancer, erlotinib, gefitinib, Ommaya, liposomal cytarabine, mafosfamide, topotecan, bevacizumab, medulloblastoma, DepoCyt, MRI, leukemia, CSF cytology
Abstract: Leptomeningeal Carcinomatosis (LC) refers to diffuse seeding of the leptomeninges by tumor metastases and is a rare presentation of solid tumors, particularly breast cancer, lung cancer and malignant melanoma in adults and hematogenous malignancies and primitive neuroectodermal tumor (PNET) in children. Recently, the incidence of LC has been reported to be increasing due to a longer overall survival obtained in patients treated with novel antineoplastic agents. The usual clinical presentation is a multifocal involvement of the neuraxis, with headache and radicular pain being the most common initial symptoms. The most frequent signs are motor deficits, altered mental status and cranial nerve involvement. The treatment of LC remains controversial and no straightforward guidelines exist in the literature. It has a bad prognosis and inevitably fatal outcome despite aggressive therapy.
Export Options
About this article
Cite this article as:
Meriggi Fausto and Zaniboni Alberto, Newer Avenues for the Treatment of Leptomeningeal Carcinomatosis, Central Nervous System Agents in Medicinal Chemistry 2011; 11 (1) . https://dx.doi.org/10.2174/187152411794961068
DOI https://dx.doi.org/10.2174/187152411794961068 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biomarker Discovery and Translation in Metabolomics
Current Metabolomics Cancer Bioinformatics for Updating Anticancer Drug Developments and Personalized Therapeutics
Reviews on Recent Clinical Trials Synthesis, Selective Cancer Cytotoxicity and Mechanistic Studies of Novel Analogs of Lantadenes
Anti-Cancer Agents in Medicinal Chemistry Hyaluronan/Hyaladherins - a Promising Axis for Targeted Drug Delivery in Cancer
Current Drug Delivery State of the Art in African Trypanosome Drug Discovery
Current Topics in Medicinal Chemistry The JAK-STAT Pathway: A Therapeutic Target in Hematological Malignancies
Current Cancer Drug Targets Synthesis, Biological Evaluation and Molecular Docking Studies Against EGFR Tyrosine Kinase of 3,5-bis(substituted benzylidene)-1- ethylpiperidin-4-one Analogues
Letters in Organic Chemistry Anti-Angiogenic Therapies for Children with Cancer
Current Cancer Drug Targets Structural Basis and Therapeutic Implication of the Interaction of CCN Proteins with Glycoconjugates
Current Pharmaceutical Design Silibinin – A Promising New Treatment for Cancer
Anti-Cancer Agents in Medicinal Chemistry Recent Trends in Nanotechnology-Based Drugs and Formulations for Targeted Therapeutic Delivery
Recent Patents on Inflammation & Allergy Drug Discovery Targeting βIII-Tubulin in Glioblastoma Multiforme: From Cell Biology and Histopathology to Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry Targeting IAPs as An Approach to Anti-Cancer Therapy
Current Topics in Medicinal Chemistry Hetero-Diels-Alder Reactions in the Synthesis of Biologically Active Nitrogen Compounds: A Review
Current Organic Synthesis Endothelial Cell Targeted Molecular Imaging in Tumor Angiogenesis: Strategies and Current Status
Current Pharmaceutical Biotechnology Bruton's Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis
Current Pharmaceutical Design Molecular Modeling, Docking, Dynamics and Simulation of Gefitinib and its Derivatives with EGFR in Non-small Cell Lung Cancer
Current Computer-Aided Drug Design Nitric Oxide and the Regulation of Apoptosis in Tumour Cells
Current Pharmaceutical Design The Anti-Proliferative Activity of Anisosciadone: A New Guaiane Sesquiterpene from Anisosciadium lanatum
Anti-Cancer Agents in Medicinal Chemistry Targeting Tumors Using Estrogen Receptor Ligand Conjugates
Current Cancer Drug Targets